| Budget Amount *help |
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2011: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2009: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Research Abstract |
It is crucial to identify biomarkers that are highly selective and sensitive in the diagnosis of cancers. We aimed to make a diagnosis platform using both antibodies and engineered lectins for detecting increased glycoprotein expression and alteration of sugar moieties accompanied with tumor progression, respectively. Two kinds of methods were applied to screen engineered lectins from randomly substituted lectin library, and several clones specific for tumor-associated glyco-antigens were obtained. Some cancer cells and specimens clearly stained with Fc-fusion proteins of these engineered lectins, which indicated that it would be a selective tool for diagnosis along with a specific antibody.
|
